Leptomeningeal Disease
Leptomeningeal disease (LMD), also termed leptomeningeal carcinomatosis or neoplastic meningitis, refers to the dissemination of metastatic tumor cells into the cerebrospinal fluid (CSF) and leptomeninges (pia and arachnoid mater). It represents one of the most devastating complications of systemic cancer, producing multifocal neurologic deficits across multiple levels of the neuraxis simultaneously. Incidence is rising due to improved survival from systemic cancer therapies and increased detection through advanced neuroimaging. LMD is reported in 5–8% of all solid tumors, though autopsy series suggest the true prevalence may be significantly higher. Despite advances in targeted therapy and immunotherapy, prognosis remains poor, with median survival of 2–4 months untreated and 4–6 months with treatment. Early recognition and a systematic diagnostic approach are critical because delayed diagnosis leads to rapid, irreversible neurologic deterioration.
Bottom Line
- Definition: Metastatic tumor cells within the CSF and leptomeninges, causing multifocal neurologic dysfunction across multiple neuraxis levels
- Most common primaries: Breast cancer (especially lobular), non-small cell lung cancer, and melanoma; hematologic malignancies (lymphoma, leukemia) also frequent
- Clinical hallmark: Simultaneous deficits at multiple neuraxis levels — cranial neuropathies, radiculopathies, and encephalopathy in the same patient
- Diagnosis: Contrast-enhanced MRI of brain + total spine (sensitivity ~70–80%) combined with CSF cytology (sensitivity ~50% on first tap, ~80% with repeat); CSF flow cytometry increases yield
- CSF flow study: Mandatory before intrathecal chemotherapy — obstructed flow leads to toxic drug accumulation and leukoencephalopathy
- Prognosis: Median survival 2–4 months without treatment, 4–6 months with treatment; emerging targeted agents (intrathecal trastuzumab for HER2+) may improve outcomes in select populations
Epidemiology and Risk Factors
LMD occurs in approximately 5–8% of patients with solid tumors over the course of their disease. The incidence has been increasing as systemic therapy improves survival, allowing time for CNS dissemination. Hematologic malignancies (acute lymphoblastic leukemia, aggressive lymphomas) have historically higher rates of leptomeningeal involvement.
| Primary Tumor | Estimated LMD Incidence | Key Features |
|---|---|---|
| Breast cancer | 5–8% | Lobular histology highest risk; triple-negative and HER2+ subtypes overrepresented |
| Non-small cell lung cancer | 3–5% | EGFR-mutant and ALK-rearranged tumors have higher CNS tropism |
| Melanoma | 5–7% | Often concurrent with parenchymal brain metastases |
| Hematologic malignancies | 5–15% | ALL, DLBCL, Burkitt lymphoma; prophylactic intrathecal therapy reduces risk |
| Gastrointestinal cancers | 1–2% | Rare but increasing recognition; gastric signet ring cell carcinoma notable |
| Primary brain tumors | 1–5% | Medulloblastoma, ependymoma, high-grade gliomas (drop metastases) |
Routes of Leptomeningeal Spread
- Hematogenous dissemination: Most common route; tumor cells reach choroid plexus or leptomeningeal vasculature via arterial blood supply
- Direct extension: From parenchymal brain metastases abutting the cortical surface or from skull base/vertebral metastases
- Perineural/perivascular spread: Along cranial or spinal nerve roots into the subarachnoid space
- Iatrogenic: Rare; surgical seeding during resection of posterior fossa tumors
Pathophysiology
Once tumor cells enter the subarachnoid space, CSF circulation facilitates widespread dissemination throughout the neuraxis. Tumor cells adhere to and invade the pia mater, cranial nerves, and spinal nerve roots. Several pathophysiologic mechanisms produce neurologic dysfunction:
- Direct infiltration: Tumor cells invade cranial nerves, spinal nerve roots, and superficial brain/spinal cord parenchyma
- CSF flow obstruction: Tumor deposits at the arachnoid granulations or within the ventricular system obstruct CSF drainage, producing communicating or obstructive hydrocephalus
- Vascular compromise: Tumor encasement of leptomeningeal vessels leads to ischemia of underlying brain and spinal cord
- Metabolic disruption: Consumption of CSF glucose by tumor cells and disruption of the blood–CSF barrier alter the neurochemical microenvironment
- Raised intracranial pressure: Hydrocephalus and increased CSF volume from impaired absorption contribute to headache, papilledema, and encephalopathy
Clinical Presentation
The clinical hallmark of LMD is multifocal neurologic deficits involving multiple levels of the neuraxis simultaneously. A patient presenting with cranial neuropathy, radiculopathy, and encephalopathy concurrently should raise immediate suspicion for leptomeningeal disease. Symptoms may be divided by neuraxis level.
| Neuraxis Level | Manifestations | Frequency |
|---|---|---|
| Cerebral/Hemispheric | Headache, nausea/vomiting, encephalopathy, seizures, cognitive decline | 50–75% |
| Cranial nerves | Diplopia (CN III, VI), facial weakness (CN VII), hearing loss (CN VIII), trigeminal neuropathy (CN V), optic neuropathy | 35–50% |
| Spinal cord | Myelopathic signs, lower extremity weakness, bowel/bladder dysfunction | 15–25% |
| Spinal roots | Radiculopathies (especially lumbosacral), cauda equina syndrome, back pain, dermatomal sensory loss | 40–60% |
Clinical Pearl: Pattern Recognition
- Cranial neuropathies: CN VI (abducens) is most commonly affected due to its long subarachnoid course; bilateral CN VI palsies suggest raised ICP or direct infiltration
- Cauda equina syndrome: Lower extremity weakness, saddle anesthesia, and areflexia in a cancer patient is LMD until proven otherwise
- Communicating hydrocephalus: Progressive headache, gait dysfunction, and cognitive decline without a focal mass lesion should prompt evaluation for LMD
- Multifocal deficits: Any combination of cranial nerve, spinal, and cerebral symptoms in a cancer patient mandates leptomeningeal workup
Red Flags: When to Suspect LMD
- New cranial neuropathy (especially CN III, VI, VII) in a patient with known cancer
- Rapidly progressive cauda equina syndrome with known malignancy
- Communicating hydrocephalus without parenchymal mass lesion
- Multifocal neurologic deficits spanning multiple neuraxis levels
- Persistent headache with meningismus in a cancer patient
- New-onset seizures with leptomeningeal enhancement on imaging
Diagnostic Evaluation
Neuroimaging
Contrast-enhanced MRI of the entire neuraxis (brain and total spine) is the imaging modality of choice. MRI has a sensitivity of approximately 70–80% for LMD and is essential for identifying sites of bulky disease, hydrocephalus, and CSF flow obstruction.
| MRI Finding | Description | Significance |
|---|---|---|
| Leptomeningeal enhancement | Linear or nodular enhancement along brain surface, cranial nerves, or spinal cord | Most characteristic finding; nodular enhancement more specific than linear |
| Cranial nerve enhancement | Abnormal thickening/enhancement of cranial nerves (especially V, VII, VIII) | High specificity when asymmetric or nodular |
| Cauda equina enhancement | Clumping, thickening, or nodular enhancement of cauda equina nerve roots | Very specific for LMD when present in cancer patients |
| Hydrocephalus | Communicating hydrocephalus without an obstructing mass | Suggests impaired CSF absorption at arachnoid granulations |
| Subependymal enhancement | Periventricular or ependymal surface enhancement | Indicates tumor spread along ventricular surfaces |
Imaging Tips
- Total spine MRI is essential: Up to 50% of patients have isolated spinal leptomeningeal disease without intracranial involvement
- Post-contrast FLAIR: More sensitive than standard T1 post-contrast for detecting leptomeningeal enhancement — should be included in the protocol
- Perform LP after MRI: Post-LP meningeal enhancement (pachymeningeal, from low pressure) can mimic or obscure leptomeningeal enhancement
- Differential diagnosis: Sarcoidosis, infectious meningitis, post-surgical changes, and autoimmune meningitis can produce similar enhancement patterns
Cerebrospinal Fluid Analysis
Lumbar puncture with CSF analysis remains the gold standard for confirming LMD. However, CSF cytology has limited sensitivity on a single sample.
| CSF Parameter | Typical Findings in LMD | Sensitivity/Notes |
|---|---|---|
| Cytology | Malignant cells identified on cytopathologic examination | ~50% on first tap; ~80% with repeat LP; 10–15 mL large-volume tap improves yield |
| Opening pressure | Elevated (>20 cm H2O) in ~50% of cases | Reflects impaired CSF absorption or hydrocephalus |
| Protein | Elevated (>50 mg/dL) in >80% of cases | Nonspecific but supportive finding |
| Glucose | Low (<60 mg/dL or <60% of serum) in ~25–40% | Consumed by metabolically active tumor cells; low glucose in cancer patient is concerning |
| Cell count | Mild pleocytosis (lymphocyte-predominant) in ~50–70% | Normal WBC count does not exclude LMD |
| Flow cytometry | Identifies clonal populations in hematologic malignancies | More sensitive than cytology for lymphoma/leukemia leptomeningeal disease |
Advanced Biomarkers and Liquid Biopsy
- CSF cell-free DNA (cfDNA): Emerging technique that detects tumor-specific mutations in CSF; sensitivity may exceed cytology, especially for low-volume disease
- CSF circulating tumor cells (CTCs): Rare cell detection technologies (CellSearch) can identify circulating tumor cells in CSF with high specificity
- CSF protein biomarkers: CEA, CA 15-3 (breast), CA 125 (ovarian) — elevated in some cases but lack specificity; useful for treatment monitoring in selected patients
- Next-generation sequencing (NGS): CSF cfDNA NGS can identify targetable mutations and guide treatment selection for LMD
Diagnostic Criteria
The EANO-ESMO guidelines classify LMD diagnosis into two categories:
- Confirmed LMD: Positive CSF cytology (or flow cytometry in hematologic malignancies)
- Probable LMD: Typical clinical presentation PLUS characteristic MRI findings, even with negative CSF cytology, in a patient with known cancer
Optimizing CSF Diagnostic Yield
- Collect ≥10 mL of CSF (large-volume tap improves sensitivity)
- Process the specimen immediately — malignant cells lyse rapidly at room temperature
- If first LP is negative, repeat LP within 1–2 weeks (sensitivity increases from ~50% to ~80%)
- Consider site-directed LP: sample CSF closest to the area of MRI abnormality (e.g., cervical tap for cranial LMD)
- Send for flow cytometry in addition to cytology when hematologic malignancy is suspected
CSF Flow Study and Ommaya Reservoir
Before initiating intrathecal chemotherapy, a radionuclide CSF flow study (ventriculography or cisternography) is essential. Obstructed CSF flow — present in 30–70% of LMD patients — leads to inadequate drug distribution and toxic accumulation at the injection site, risking severe leukoencephalopathy.
| Component | Details |
|---|---|
| CSF flow study | Radiolabeled tracer (In-111 DTPA or Tc-99m) injected intrathecally; serial imaging at 1, 4, and 24 hours to assess flow |
| Normal flow | Tracer reaches basal cisterns by 1–4 hours and cerebral convexities by 24 hours |
| Obstructed flow | Absent or delayed tracer transit indicates CSF block — focal radiation to obstruction site before intrathecal therapy |
| Ommaya reservoir | Subcutaneous dome connected to ventricular catheter; allows repeated intrathecal drug delivery without repeated LPs |
| Ommaya complications | Infection (5–10%), catheter malposition, hemorrhage, leukoencephalopathy from drug reflux |
Critical: Intrathecal Chemotherapy Safety
- Never administer intrathecal chemotherapy without confirming CSF flow patency — obstructed flow leads to toxic drug levels at the injection site
- Obstructed flow occurs in 30–70% of LMD patients and is often clinically silent
- Focal radiation to sites of CSF obstruction can restore flow in ~30% of patients
- Intrathecal methotrexate with impaired flow is a major risk factor for necrotizing leukoencephalopathy
Treatment
Treatment of LMD is multimodal and primarily palliative. Goals include neurologic stabilization, symptom palliation, and modest survival prolongation. Treatment decisions should be individualized based on performance status, tumor biology, extent of disease, and systemic treatment options.
Intrathecal Chemotherapy
| Agent | Dosing | Key Considerations |
|---|---|---|
| Methotrexate (IT) | 12 mg twice weekly × 4 weeks, then weekly, then monthly | Most widely used; supplement with oral leucovorin (folinic acid) to reduce systemic toxicity; monitor for leukoencephalopathy |
| Cytarabine (IT) | 50 mg twice weekly or liposomal (DepoCyt) 50 mg every 2 weeks | Liposomal formulation allows less frequent dosing; co-administer dexamethasone to prevent chemical arachnoiditis |
| Thiotepa (IT) | 10 mg twice weekly | Less commonly used; alternative when methotrexate and cytarabine are contraindicated |
| Trastuzumab (IT) | 150 mg weekly (investigational) | Emerging for HER2+ breast cancer LMD; encouraging response rates in clinical trials |
Radiation Therapy
- Focal/involved-field radiation: Directed at bulky or symptomatic sites (e.g., cauda equina, cranial base); effective for pain relief and neurologic stabilization
- Whole-brain radiation therapy (WBRT): Generally avoided due to neurotoxicity; reserved for diffuse intracranial disease without systemic options
- Craniospinal irradiation (CSI): Rarely used due to severe myelosuppression; limited to select primary CNS tumors (medulloblastoma) or young patients with good performance status
- Proton therapy: Being investigated for CSI with reduced hematologic toxicity
Systemic Therapy with CNS Penetration
| Agent/Class | CNS Penetration | Tumor Types |
|---|---|---|
| High-dose methotrexate (IV) | Good at ≥3 g/m2 | CNS lymphoma, selected solid tumors |
| Osimertinib | High | EGFR-mutant NSCLC (BLOOM trial data) |
| Tucatinib + trastuzumab/capecitabine | Moderate | HER2+ breast (HER2CLIMB data) |
| Lorlatinib | High | ALK-rearranged NSCLC |
| Capecitabine | Moderate | Breast cancer |
| Temozolomide | Good | Melanoma (limited efficacy) |
| Ipilimumab/nivolumab | Variable | Melanoma LMD (CheckMate 204 leptomeningeal cohort) |
Management of Hydrocephalus
- Ventriculoperitoneal (VP) shunt: Provides symptomatic relief from hydrocephalus; consider in patients with reasonable performance status and life expectancy
- Endoscopic third ventriculostomy (ETV): Alternative for obstructive hydrocephalus caused by tumor deposits at the aqueduct
- Serial therapeutic lumbar punctures: Temporizing measure for symptom relief before definitive CSF diversion
Treatment Algorithm
- Step 1: Confirm diagnosis (CSF cytology/flow cytometry + MRI neuraxis)
- Step 2: Assess CSF flow (radionuclide flow study); irradiate obstructing lesions if present
- Step 3: Place Ommaya reservoir if intrathecal therapy planned
- Step 4: Initiate intrathecal chemotherapy (methotrexate or cytarabine) PLUS systemic therapy with CNS penetration
- Step 5: Focal radiation to bulky or symptomatic sites
- Step 6: VP shunt if symptomatic hydrocephalus persists
- Step 7: Monitor with serial CSF cytology and MRI every 6–8 weeks
Prognosis and Prognostic Factors
Prognosis of LMD remains poor across all tumor types. Median overall survival is 2–4 months without treatment and 4–6 months with combined-modality therapy. Select patients with favorable tumor biology and good performance status may achieve longer survival.
| Prognostic Factor | Favorable | Unfavorable |
|---|---|---|
| Performance status | KPS ≥70 | KPS <60 |
| Tumor type | Breast (HER2+), hematologic | Melanoma, NSCLC (non-driver mutation) |
| Neurologic deficit severity | Minimal or single-domain | Multifocal, encephalopathy |
| CSF flow | Patent | Obstructed (limits treatment efficacy) |
| Systemic disease control | Stable or responsive | Progressive, refractory |
| Targetable mutation | Present (EGFR, ALK, HER2) | Absent |
Emerging Therapies and Future Directions
- Intrathecal trastuzumab: Phase I/II trials show encouraging CSF cytology conversion rates and improved survival in HER2+ breast cancer LMD
- Intrathecal nivolumab: Early-phase trials investigating intrathecal checkpoint inhibitors for melanoma and NSCLC LMD
- CSF liquid biopsy: cfDNA analysis for real-time monitoring of treatment response and detection of resistance mutations
- CAR-T cell therapy: Intrathecal or intraventricular CAR-T cells being explored for CNS lymphoma and selected solid tumor LMD
- Convection-enhanced delivery: Investigational method for improved drug distribution throughout the subarachnoid space
- Targeted agents with CNS penetration: Osimertinib (EGFR), lorlatinib (ALK), tucatinib (HER2) have demonstrated activity in LMD cohorts of clinical trials
Special Populations
Hematologic Malignancies
Leptomeningeal involvement in hematologic malignancies (ALL, DLBCL, Burkitt lymphoma) differs from solid tumor LMD in several important ways:
- Higher response rates: Hematologic LMD generally responds better to intrathecal chemotherapy than solid tumor LMD
- Prophylaxis is standard: CNS prophylaxis with intrathecal methotrexate/cytarabine or high-dose systemic methotrexate is standard of care in high-risk hematologic malignancies
- Flow cytometry is preferred: More sensitive than cytology for detecting clonal lymphocyte populations in CSF
- Systemic high-dose methotrexate: Doses ≥3 g/m2 achieve therapeutic CSF levels and may be used alone or with intrathecal therapy
Primary Brain Tumors
- Medulloblastoma: Highest risk of leptomeningeal dissemination among pediatric CNS tumors; craniospinal irradiation is standard
- Glioblastoma: Leptomeningeal spread occurs in 2–4%; often presents as linear enhancement along surgical cavity margins or distant from primary site
- Ependymoma: Drop metastases to the spinal subarachnoid space; total spine MRI required at diagnosis and surveillance
References
- Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol. 2010;22(6):627-635.
- Le Rhun E, Weller M, Brandsma D, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017;28(suppl_4):iv84-iv99.
- Nayar G, Ejikeme T, Chongsathidkiet P, et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget. 2017;8(42):73312-73328.
- Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394-3402.
- Bousquet G, Darrouzain F, de Bazelaire C, et al. Intrathecal trastuzumab halts progression of CNS metastases in breast cancer. J Clin Oncol. 2016;34(16):e151-e155.
- Brastianos PK, Lee EQ, Cohen JV, et al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med. 2020;26(8):1280-1284.
- Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25(2):103-119.
- Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006;5(5):443-452.
- Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49(4):759-772.
- Mack F, Baumert BG, Schäfer N, et al. Therapy of leptomeningeal metastasis in solid tumors. Cancer Treat Rev. 2016;43:83-91.
- Yang JCH, Kim SW, Kim DW, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol. 2020;38(6):538-547.
- Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg. 1997;87(5):694-699.